SRR8518162
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.560
- E2F_TARGETS+0.500
- INTERFERON_GAMMA_RESPONSE+0.470
- G2M_CHECKPOINT+0.450
- MYC_TARGETS_V1+0.340
- UNFOLDED_PROTEIN_RESPONSE+0.320
- ALLOGRAFT_REJECTION+0.310
- SPERMATOGENESIS+0.250
- IL6_JAK_STAT3_SIGNALING+0.240
- MYC_TARGETS_V2+0.240
Top 10 suppressed
- ANGIOGENESIS-0.470
- NOTCH_SIGNALING-0.440
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.420
- HEDGEHOG_SIGNALING-0.360
- ADIPOGENESIS-0.320
- MYOGENESIS-0.310
- WNT_BETA_CATENIN_SIGNALING-0.300
- BILE_ACID_METABOLISM-0.270
- COAGULATION-0.270
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR25043627 | — | — | 0.885 |
| 2 | SRR1313144 | — | D | 0.866 |
| 3 | TCGA-CN-A499-01A-11R-A24H-07 | — | — | 0.865 |
| 4 | TCGA-C8-A1HM-01A-12R-A137-07 | — | C | 0.842 |
| 5 | SRR4195655 | — | — | 0.841 |
| 6 | MBCProject_1819_T1_RNA | — | C | 0.836 |
| 7 | b25e7003-40df-4806-baee-eb8ad1c69643 | — | — | 0.830 |
| 8 | SRR8518291 | — | D | 0.826 |
| 9 | SRR12475138 | — | — | 0.820 |
| 10 | TCGA-E2-A1LI-01A-12R-A157-07 | — | E | 0.820 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.560 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.470 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.450 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.340 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.320 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.310 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.250 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.240 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.240 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.220 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.210 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.190 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.150 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.120 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.090 | Cobimetinib | — uncovered |
| ANDROGEN_RESPONSE | 0.080 | Inavolisib | — uncovered |
| COMPLEMENT | 0.080 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.080 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.060 | Remibrutinib | — uncovered |